After Biogen announced that its CEO would depart, BMO Capital analyst M. Ian Somaiya doesn't think that the news implies that the company will be acquired. The analyst says that the company's Q2 EPS beat expectations due to cost cutting, while the company's new guidance "sets a very low bar." The analyst keeps a Market Perform rating on the stock.
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here